Business Wire

EUNETWORKS

19.12.2022 09:31:42 CET | Business Wire | Press release

Share
euNetworks appoints Stephanie Lynch-Habib to President

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the appointment of Stephanie Lynch-Habib to the leadership team, taking up the role of President, euNetworks, with responsibility for all operating aspects of the business. This appointment is effective 15 January 2023. Stephanie’s appointment follows the recent announcement that Paula Cogan will take up the role of euNetworks’ Chief Executive Officer as Brady Rafuse moves to become euNetworks’ Chairman of the Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221219005195/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Stephanie Lynch-Habib (Photo: Business Wire)

Stephanie joins euNetworks following more than 25 years working in the telecom and technology industry. Most recently she was Chief Revenue Officer at InterCloud in Paris, responsible for driving growth opportunities for the business. Before joining InterCloud Stephanie led the global marketing and communications strategy of the GSMA, the global organisation representing mobile operators and organisations across the mobile ecosystem and adjacent industries. She has also held the position of Chief Marketing Officer at Colt, responsible for marketing strategy and prior to that, spent 16 years with AT&T EMEA, holding numerous senior marketing, sales, and strategy roles. While at AT&T, Stephanie was a founder of the AT&T European Women's Network. She has been recognised for her leading position in the sector, while also contributing to various women’s sector initiatives globally. Her global and European experience fit perfectly with the demands she will face as President at euNetworks.

“We are absolutely delighted to welcome Stephanie to euNetworks,” said Paula Cogan. “She’s a great addition to the team and fills a critical position in the business. I am excited for the contributions that Stephanie will make to euNetworks as I move to take up the role of Chief Executive Officer of euNetworks in January. Along with Stephanie’s global leadership experience, her advocacy, and efforts for strong women representation in the telecom sector is commendable and we welcome her contribution to euNetworks’ diversity and inclusion focus as well as in the wider industry.”

“Stephanie is a leader in the industry with extensive expertise, and she will be a great addition to the team,” said Cyrus Gentry, Managing Director and Head of Communications, Europe at Stonepeak. “Stephanie’s appointment is key to the strategic growth plan we are enacting at euNetworks, and we welcome her onboard and look forward to working with her.”

“I have watched the company develop and grow over the years with much admiration, and have worked with euNetworks as a customer most recently,” said Stephanie Lynch-Habib. “euNetworks’ reputation in the industry and among its customer base, who comprise the largest consumers of bandwidth in both Europe and globally, is exceptional. I am thrilled to be joining the team, and excited for the opportunity ahead for us all.”

About euNetworks

euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 490 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005195/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye